OncoMatch/Clinical Trials/NCT05754749
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
Is NCT05754749 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Iohexol 350 Mg/mL Injectable Solution for breast cancer.
Treatment: Iohexol 350 Mg/mL Injectable Solution — The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesions between contrast enhanced digital breast tomosynthesis (CE- DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI) acquired as a part of a standard clinical workup.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Lab requirements
Kidney function
serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels within the last 30 days prior to the research scan unless anuric and on dialysis
Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels within the last 30 days prior to the research scan) unless anuric and on dialysis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify